Interfaces with obesity and associated metabolic disorders: Prospectively test whether targeting inflammation/energy metabolism (e.g., NLRP3/IL-6 pathways, statins/metformin/colchicine) disrupts the obesity–CHIP feedback loop and improves cardiometabolic outcomes. Here, NLRP3 is linked to obesity disorder.